Non-Interventional Prospective Observational Study of Platelet Rich Fibrin as a Therapy Adjunctive in Patients with Medication-Related Osteonecrosis of the Jaw
<p>Exemplary surgical procedures in study arm (<b>B</b>): (<b>A</b>) Preoperative situation with MRONJ stage II of the right mandible with exudation of pus. (<b>B</b>) Intraoperative situation after tooth extraction and decortication. (<b>C</b>) Pressed PRF. (<b>D</b>) PRF covering the decorticated bone. (<b>E</b>) Mechanically stable covering with soft tissue.</p> "> Figure 2
<p>Illustration of patient acquisition and full exclusion details.</p> "> Figure 3
<p>The IPR wound healing score showed no statistical differences between study arm A (−PRF, red boxplot) and B (+PRF, blue boxplot, <span class="html-italic">p</span> = 0.302).</p> "> Figure 4
<p>Analysis of the PWAT score did not display any statistically significant differences between the study arms (Arm A: −PRF, Arm B: +PRF, V2 <span class="html-italic">p</span> = 0.222, V3 <span class="html-italic">p</span> = 0.504, V4 <span class="html-italic">p</span> = 0.3017).</p> "> Figure 5
<p>Analysis of the VAS score did not display any statistically significant differences between the study arms (Arm A: −PRF, Arm B: +PRF, V2 <span class="html-italic">p</span> = 0.169, V3 <span class="html-italic">p</span> = 0.406, V4 <span class="html-italic">p</span> = 0.155).</p> "> Figure 6
<p>Analysis of the PWAT score did not display any statistical significances between the study arms (Arm A: −PRF, Arm B: +PRF, V2 <span class="html-italic">p</span> = 0.222, V3 <span class="html-italic">p</span> = 0.504, V4 <span class="html-italic">p</span> = 0.3017).</p> ">
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Setting
2.3. Participants
2.4. Variables, Data Sources/Measurement
2.5. Study Size
2.6. Statistical Analysis
3. Results
3.1. Participants
3.2. Descriptive Data
3.3. Outcome Data
3.4. Other Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bamias, A.; Kastritis, E.; Bamia, C.; Moulopoulos, L.A.; Melakopoulos, I.; Bozas, G.; Koutsoukou, V.; Gika, D.; Anagnostopoulos, A.; Papadimitriou, C.; et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J. Clin. Oncol. 2005, 23, 8580–8587. [Google Scholar] [CrossRef] [PubMed]
- Walter, C.; Al-Nawas, B.; Grötz, K.A.; Thomas, C.; Thüroff, J.W.; Zinser, V.; Gamm, H.; Beck, J.; Wagner, W. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur. Urol. 2008, 54, 1066–1072. [Google Scholar] [CrossRef] [PubMed]
- Marx, R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J. Oral Maxillofac. Surg. 2003, 61, 1115–1117. [Google Scholar] [CrossRef]
- Khan, A.A.; Morrison, A.; Hanley, D.A.; Felsenberg, D.; McCauley, L.K.; O’Ryan, F.; Reid, I.R.; Ruggiero, S.L.; Taguchi, A.; Tetradis, S.; et al. Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. J. Bone Miner. Res. 2015, 30, 3–23. [Google Scholar] [CrossRef]
- Ruggiero, S.L.; Dodson, T.B.; Fantasia, J.; Goodday, R.; Aghaloo, T.; Mehrotra, B.; O’Ryan, F.; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteone-crosis of the jaw—2014 update. J. Oral Maxillofac. Surg. 2014, 72, 1938–1956. [Google Scholar] [CrossRef]
- Capocci, M.; Romeo, U.; Guerra, F.; Mannocci, A.; Tenore, G.; Annibali, S.; Ottolenghi, L. Medication-related osteonecrosis of the jaws (MRONJ) and quality of life evaluation: A pilot study. Clin. Ther. 2017, 168, 253–257. [Google Scholar] [CrossRef]
- Reid, I.R.; Cornish, J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat. Rev. Rheumatol. 2011, 8, 90–96. [Google Scholar] [CrossRef]
- El-Rabbany, M.; Sgro, A.; Lam, D.K.; Shah, P.S.; Azarpazhooh, A. Effectiveness of treatments for medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. J. Am. Dent. Assoc. 2017, 148, 584–594.e2. [Google Scholar] [CrossRef]
- King, R.; Tanna, N.; Patel, V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab—A review. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2019, 127, 289–299. [Google Scholar] [CrossRef]
- Bennardo, F.; Buffone, C.; Giudice, A. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws. Oral Oncol. 2020, 106, 104659. [Google Scholar] [CrossRef]
- Chang, J.; Hakam, A.E.; McCauley, L.K. Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw. Curr. Osteoporos. Rep. 2018, 16, 584–595. [Google Scholar] [CrossRef] [PubMed]
- Paulo, S.; Abrantes, A.M.; Laranjo, M.; Carvalho, L.; Serra, A.; Botelho, M.F.; Ferreira, M.M. Bisphosphonate-related osteonecrosis of the jaw: Specificities. Oncol. Rev. 2014, 8, 254. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wehrhan, F.; Stockmann, P.; Nkenke, E.; Schlegel, K.A.; Guentsch, A.; Wehrhan, T.; Neukam, F.W.; Amann, K. Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol. 2011, 112, 216–221. [Google Scholar] [CrossRef] [PubMed]
- Giudice, A.; Antonelli, A.; Chiarella, E.; Baudi, F.; Barni, T.; Di Vito, A. The Case of Medication-Related Osteonecrosis of the Jaw Addressed from a Pathogenic Point of View. Innovative Therapeutic Strategies: Focus on the Most Recent Discoveries on Oral Mesenchymal Stem Cell-Derived Exosomes. Pharmaceuticals 2020, 13, 423. [Google Scholar] [CrossRef]
- Di Vito, A.; Chiarella, E.; Baudi, F.; Scardamaglia, P.; Antonelli, A.; Giudice, D.; Barni, T.; Fortunato, L.; Giudice, A. Dose-Dependent Effects of Zoledronic Acid on Human Periodontal Ligament Stem Cells: An In Vitro Pilot Study. Cell Transplant. 2020, 29, 0963689720948497. [Google Scholar] [CrossRef] [PubMed]
- Schiodt, M.; Otto, S.; Fedele, S.; Bedogni, A.; Nicolatou-Galitis, O.; Guggenberger, R.; Herlofson, B.B.; Ristow, O.; Kofod, T. Workshop of European task force on medication-related osteonecrosis of the jaw—Current challenges. Oral Dis. 2019, 25, 1815–1821. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ristow, O.; Rückschloß, T.; Bodem, J.; Berger, M.; Bodem, E.; Kargus, S.; Engel, M.; Hoffmann, J.; Freudlsperger, C. Double-layer closure techniques after bone surgery of medication-related osteonecrosis of the jaw—A single center cohort study. J. Cranio-Maxillofac. Surg. 2018, 46, 815–824. [Google Scholar] [CrossRef]
- Yoshiga, D.; Nakamichi, I.; Yamashita, Y.; Yamamoto, N.; Yamauchi, K.; Nogami, S.; Kaneuji, T.; Mitsugi, S.; Tanaka, K.; Kataoka, Y.; et al. Prognosis factors in the treatment of bisphosphonate-related osteonecrosis of the jaw—Prognostic factors in the treatment of BRONJ. J. Clin. Exp. Dent. 2014, 6, e22–e28. [Google Scholar] [CrossRef]
- Klingelhöffer, C.; Zeman, F.; Meier, J.; Reichert, T.E.; Ettl, T. Evaluation of surgical outcome and influencing risk factors in patients with medication-related oste-onecrosis of the jaws. J. Cranio-Maxillofac. Surg. 2016, 44, 1694–1699. [Google Scholar] [CrossRef]
- Ristow, O.; Nehrbass, D.; Zeiter, S.; Arens, D.; Moratin, J.; Pautke, C.; Hoffmann, J.; Freudlsperger, C.; Otto, S. Differences between auto-fluorescence and tetracycline-fluorescence in medication-related osteonecrosis of the jaw—a preclinical proof of concept study in the mini-pig. Clin. Oral Investig. 2020, 24, 4625–4637. [Google Scholar] [CrossRef]
- Asaka, T.; Ohga, N.; Yamazaki, Y.; Sato, J.; Satoh, C.; Kitagawa, Y. Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: A trial study. Clin. Oral Investig. 2017, 21, 2165–2172. [Google Scholar] [CrossRef] [PubMed]
- Park, J.H.; Kim, J.W.; Kim, S.J. Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw? J. Oral Maxillofac. Surg. 2017, 75, 1176–1184. [Google Scholar] [CrossRef] [Green Version]
- Dohan, D.M.; Choukroun, J.; Diss, A.; Dohan, S.L.; Dohan, A.J.; Mouhyi, J.; Gogly, B. Platelet-rich fibrin (PRF): A second-generation platelet concentrate. Part I: Technological concepts and evolution. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol. 2006, 101, e37–e44. [Google Scholar] [CrossRef]
- Miron, R.J.; Zucchelli, G.; Pikos, M.A.; Salama, M.; Lee, S.; Guillemette, V.; Fujioka-Kobayashi, M.; Bishara, M.; Zhang, Y.; Wang, H.-L.; et al. Use of platelet-rich fibrin in regenerative dentistry: A systematic review. Clin. Oral Investig. 2017, 21, 1913–1927. [Google Scholar] [CrossRef] [PubMed]
- Fortunato, L.; Barone, S.; Bennardo, F.; Giudice, A. Management of Facial Pyoderma Gangrenosum Using Platelet-Rich Fibrin: A Technical Report. J. Oral Maxillofac. Surg. 2018, 76, 1460–1463. [Google Scholar] [CrossRef] [PubMed]
- Beth-Tasdogan, N.H.; Mayer, B.; Hussein, H.; Zolk, O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst. Rev. 2017, 10, Cd012432. [Google Scholar] [CrossRef]
- Hamzani, Y.; Chaushu, G. Evaluation of early wound healing scales/indexes in oral surgery: A literature review. Clin. Implant. Dent. Relat. Res. 2018, 20, 1030–1035. [Google Scholar] [CrossRef]
- Thompson, N.; Gordey, L.; Bowles, H.; Parslow, N.; Houghton, P. Reliability and validity of the revised photographic wound assessment tool on digital images taken of various types of chronic wounds. Adv. Ski. Wound Care 2013, 26, 360–373. [Google Scholar] [CrossRef]
- Schmalz, G.; Patschan, D.; Schmickler, J.; Bethke, N.; Scherzinger, E.; Müller, G.A.; Ziebolz, D.; Patschan, S. Oral health-related quality of life in different rheumatic diseases. Oral Dis. 2020, 26, 1783–1792. [Google Scholar] [CrossRef]
- Kang, M.-H.; Lee, D.-K.; Kim, C.-W.; Song, I.-S.; Jun, S.-H. Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw. J. Korean Assoc. Oral Maxillofac. Surg. 2018, 44, 225–231. [Google Scholar] [CrossRef] [Green Version]
- Carlson, E.R.; Basile, J.D. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 2009, 67 (Suppl. S5), 85–95. [Google Scholar] [CrossRef] [PubMed]
- Hsu, K.-J.; Hsiao, S.-Y.; Chen, P.-H.; Chen, H.-S.; Chen, C.-M. Investigation of the Effectiveness of Surgical Treatment on Maxillary Medication-Related Osteonecrosis of the Jaw: A Literature Review. J. Clin. Med. 2021, 10, 4480. [Google Scholar] [CrossRef] [PubMed]
- Otto, S.; Aljohani, S.; Fliefel, R.; Ecke, S.; Ristow, O.; Burian, E.; Troeltzsch, M.; Pautke, C.; Ehrenfeld, M. Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ). Medicina 2021, 57, 463. [Google Scholar] [CrossRef] [PubMed]
- Gao, S.-Y.; Zheng, G.-S.; Wang, L.; Liang, Y.-J.; Zhang, S.-E.; Lao, X.-M.; Li, K.; Liao, G.-Q. Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB. PLoS ONE 2017, 12, e0179248. [Google Scholar] [CrossRef] [PubMed]
- Kuroshima, S.; Sasaki, M.; Murata, H.; Sawase, T. Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis. Gerodontology 2019, 36, 313–324. [Google Scholar] [CrossRef]
- Zhang, W.; Gao, L.; Ren, W.; Li, S.; Zheng, J.; Li, S.; Jiang, C.; Yang, S.; Zhi, K. The Role of the Immune Response in the Development of Medication-Related Osteonecrosis of the Jaw. Front. Immunol. 2021, 12, 606043. [Google Scholar] [CrossRef]
- Paschalidi, P.; Gkouveris, I.; Soundia, A.; Kalfarentzos, E.; Vardas, E.; Georgaki, M.; Kostakis, G.; Erovic, B.M.; Tetradis, S.; Perisanidis, C.; et al. The role of M1 and M2 macrophage polarization in progression of medication-related osteonecrosis of the jaw. Clin. Oral Investig. 2021, 25, 2845–2857. [Google Scholar] [CrossRef]
- Blatt, S.; Burkhardt, V.; Kämmerer, P.W.; Pabst, A.M.; Sagheb, K.; Heller, M.; Al-Nawas, B.; Schiegnitz, E. Biofunctionalization of porcine-derived collagen matrices with platelet rich fibrin: Influence on angiogenesis in vitro and in vivo. Clin. Oral Investig. 2020, 24, 3425–3436. [Google Scholar] [CrossRef] [Green Version]
- Blatt, S.; Thiem, D.G.E.; Kyyak, S.; Pabst, A.; Al-Nawas, B.; Kämmerer, P.W. Possible Implications for Improved Osteogenesis? The Combination of Platelet-Rich Fibrin with Different Bone Substitute Materials. Front. Bioeng. Biotechnol. 2021, 9, 640053. [Google Scholar] [CrossRef]
- Blatt, S.; Thiem, D.G.E.; Pabst, A.; Al-Nawas, B.; Kämmerer, P.W. Does Platelet-Rich Fibrin Enhance the Early Angiogenetic Potential of Different Bone Substitute Materials? An In Vitro and In Vivo Analysis. Biomedicines 2021, 9, 61. [Google Scholar] [CrossRef]
- Kyyak, S.; Blatt, S.; Pabst, A.; Thiem, D.; Al-Nawas, B.; Kämmerer, P.W. Combination of an allogenic and a xenogenic bone substitute material with injectable platelet-rich fibrin—A comparative in vitro study. J. Biomater. Appl. 2020, 35, 83–96. [Google Scholar] [CrossRef] [PubMed]
- Kyyak, S.; Blatt, S.; Schiegnitz, E.; Heimes, D.; Staedt, H.; Thiem, D.G.E.; Sagheb, K.; Al-Nawas, B.; Kämmerer, P.W. Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials with and Without Injectable Platelet Rich Fibrin in vitro. Front. Bioeng. Biotechnol. 2021, 9, 599224. [Google Scholar] [CrossRef] [PubMed]
- Xiong, G.; Lingampalli, N.; Koltsov, J.C.; Leung, L.L.; Bhutani, N.; Robinson, W.H.; Chu, C.R. Men and Women Differ in the Biochemical Composition of Platelet-Rich Plasma. Am. J. Sports Med. 2018, 46, 409–419. [Google Scholar] [CrossRef] [PubMed]
- Miron, R.J.; Dham, A.; Dham, U.; Zhang, Y.; Pikos, M.A.; Sculean, A. The effect of age, gender, and time between blood draw and start of centrifugation on the size outcomes of platelet-rich fibrin (PRF) membranes. Clin. Oral Investig. 2019, 23, 2179–2185. [Google Scholar] [CrossRef] [PubMed]
- Mamajiwala, A.S.; Sethi, K.S.; Raut, C.P.; Karde, P.A.; Mangle, N.M. Impact of different platelet-rich fibrin (PRF) procurement methods on the platelet count, antimicrobial efficacy, and fibrin network pattern in different age groups: An in vitro study. Clin. Oral Investig. 2020, 24, 1663–1675. [Google Scholar] [CrossRef] [PubMed]
- Tornier, S.D.C.; Macedo, F.J.; Sassi, L.M.; Schussel, J.L. Quality of life in cancer patients with or without medication-related osteonecrosis of the jaw. Support. Care Cancer 2021, 29, 6713–6719. [Google Scholar] [CrossRef]
- Di Fede, O.; Canepa, F.; Panzarella, V.; Mauceri, R.; Del Gaizo, C.; Bedogni, A.; Fusco, V.; Tozzo, P.; Pizzo, G.; Campisi, G.; et al. The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols. Int. J. Environ. Res. Public Health 2021, 18, 8432. [Google Scholar] [CrossRef]
- Govaerts, D.; Piccart, F.; Ockerman, A.; Coropciuc, R.; Politis, C.; Jacobs, R. Adjuvant therapies for MRONJ: A systematic review. Bone 2020, 141, 115676. [Google Scholar] [CrossRef]
- Albertos, C.S.-G.; de Vera, J.D.C.P.; Llorente, A.V.; Carretero, J.C. Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) placement. Med. Oral Patol. Oral Cir. Bucal 2021, 26, e684–e690. [Google Scholar] [CrossRef]
- Inchingolo, F.; Cantore, S.; Dipalma, G.; Georgakopoulos, I.; Almasri, M.; Gheno, E.; Marzullo, A.; Motta, A.; Marrelli, M.; Farronato, D.; et al. Platelet rich fibrin in the management of medication-related osteonecrosis of the jaw: A clinical and his-topathological evaluation. J. Biol. Regul. Homeost. Agents 2017, 31, 811–816. [Google Scholar]
- Mourão, C.F.D.A.B.; Calasans-Maia, M.D.; Del Fabbro, M.; Vieira, F.L.D.; de Mello Machado, R.C.; Capella, R.; Miron, R.J.; Alves, G.G. The use of Platelet-rich Fibrin in the management of medication-related oste-onecrosis of the jaw: A case series. J. Stomatol. Oral Maxillofac. Surg. 2020, 121, 84–89. [Google Scholar]
- Soydan, S.S.; Uckan, S. Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: Technical report. J. Oral Maxillofac. Surg. 2014, 72, 322–326. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.-W.; Kim, S.-J.; Kim, M.-R. Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: A prospective feasibility study. Br. J. Oral Maxillofac. Surg. 2014, 52, 854–859. [Google Scholar] [CrossRef]
- Giudice, A.; Antonelli, A.; Muraca, D.; Fortunato, L. Usefulness of advanced-platelet rich fibrin (A-PRF) and injectable-platelet rich fibrin (i-PRF) in the man-agement of a massive medication-related osteonecrosis of the jaw (MRONJ): A 5-years follow-up case report. Indian J. Dent. Res. 2020, 31, 813–818. [Google Scholar] [PubMed]
- Cano-Durán, J.A.; Peña-Cardelles, J.-F.; Ortega-Concepción, D.; Paredes-Rodríguez, V.M.; García-Riart, M.; López-Quiles, J. The role of Leucocyte-rich and platelet-rich fibrin (L-PRF) in the treatment of the medication-related osteonecrosis of the jaws (MRONJ). J. Clin. Exp. Dent. 2017, 9, e1051–e1059. [Google Scholar] [CrossRef] [PubMed]
- Fortunato, L.; Bennardo, F.; Buffone, C.; Giudice, A. Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review. J. Cranio-Maxillofac. Surg. 2020, 48, 268–285. [Google Scholar] [CrossRef] [PubMed]
- Trybek, G.; Rydlińska, J.; Aniko-Włodarczyk, M.; Jaroń, A. Effect of Platelet-Rich Fibrin Application on Non-Infectious Complications after Surgical Extraction of Im-pacted Mandibular Third Molars. Int. J. Environ. Res. Public Health 2021, 18, 8249. [Google Scholar] [CrossRef] [PubMed]
- Temmerman, A.; Cleeren, G.J.; Castro, A.B.; Teughels, W.; Quirynen, M. L-PRF for increasing the width of keratinized mucosa around implants: A split-mouth, randomized, controlled pilot clinical trial. J. Periodontal Res. 2018, 53, 793–800. [Google Scholar] [CrossRef]
- Fortunato, L.; Amato, M.; Simeone, M.; Bennardo, F.; Barone, S.; Giudice, A. Numb chin syndrome: A reflection of malignancy or a harbinger of MRONJ? A multicenter experience. J. Stomatol. Oral Maxillofac. Surg. 2018, 119, 389–394. [Google Scholar] [CrossRef]
- Sánchez, M.; Anitua, E.; Delgado, D.; Sanchez, P.; Prado, R.; Orive, G.; Padilla, S. Platelet-rich plasma, a source of autologous growth factors and biomimetic scaffold for peripheral nerve regeneration. Expert Opin. Biol. Ther. 2017, 17, 197–212. [Google Scholar] [CrossRef]
- Del Fabbro, M.; Gallesio, G.; Mozzati, M. Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature. Eur. J. Cancer 2015, 51, 62–74. [Google Scholar] [CrossRef] [PubMed]
- Otto, S.; Pautke, C.; Arens, D.; Poxleitner, P.; Eberli, U.; Nehrbass, D.; Zeiter, S.; Stoddart, M.J. A Drug Holiday Reduces the Frequency and Severity of Medication-Related Osteonecrosis of the Jaw in a Minipig Model. J. Bone Miner. Res. 2020, 35, 2179–2192. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.-W.; Kwak, M.K.; Han, J.J.; Lee, S.-T.; Kim, H.Y.; Kim, S.H.; Jung, J.; Lee, J.K.; Lee, Y.-K.; Kwon, Y.-D.; et al. Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J. Bone Metab. 2021, 28, 279–296. [Google Scholar] [CrossRef] [PubMed]
- Ristow, O.; Rückschloß, T.; Müller, M.; Berger, M.; Kargus, S.; Pautke, C.; Engel, M.; Hoffmann, J.; Freudlsperger, C. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study. J. Cranio-Maxillofac. Surg. 2019, 47, 491–499. [Google Scholar] [CrossRef]
- Otto, S.; Pautke, C.; Van den Wyngaert, T.; Niepel, D.; Schiødt, M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat. Rev. 2018, 69, 177–187. [Google Scholar] [CrossRef]
- Giudice, A.; Barone, S.; Diodati, F.; Antonelli, A.; Nocini, R.; Cristofaro, M.G. Can Surgical Management Improve Resolution of Medication-Related Osteonecrosis of the Jaw at Early Stages? A Prospective Cohort Study. J. Oral Maxillofac. Surg. 2020, 78, 1986–1999. [Google Scholar] [CrossRef]
- Tenore, G.; Zimbalatti, A.; Rocchetti, F.; Graniero, F.; Gaglioti, D.; Mohsen, A.; Caputo, M.; Lollobrigida, M.; Lamazza, L.; De Biase, A.; et al. Management of Medication-Related Osteonecrosis of the Jaw (MRONJ) Using Leukocyte- and Platelet-Rich Fibrin (L-PRF) and Photobiomodulation: A Retrospective Study. J. Clin. Med. 2020, 9, 3505. [Google Scholar] [CrossRef]
Visit 1 (Screening) | Visit 2 (5th Day Post op.) | Visit 3 (14th Day Post op) | Visit 4 (42nd Day Post op.) | |
---|---|---|---|---|
Informed consent | X | |||
In-/exclusion criteria | X | X | ||
Demographic/baseline characteristics | X | |||
Staging according to AAOMS | X | X | X | X |
VAS | X | X | X | |
OHIP G14 | X | X | X | |
IPR | X | X | X | |
PWAT | X | X | X | |
discharge | X | |||
Suture removal | X | |||
resumption of antiresorptive therapy | X | |||
Adverse events | X | X | X | |
Medication | X | X | X | X |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Blatt, S.; Krüger, M.; Kämmerer, P.W.; Thiem, D.G.E.; Matheis, P.; Eisenbeiß, A.-K.; Wiltfang, J.; Al-Nawas, B.; Naujokat, H. Non-Interventional Prospective Observational Study of Platelet Rich Fibrin as a Therapy Adjunctive in Patients with Medication-Related Osteonecrosis of the Jaw. J. Clin. Med. 2022, 11, 682. https://doi.org/10.3390/jcm11030682
Blatt S, Krüger M, Kämmerer PW, Thiem DGE, Matheis P, Eisenbeiß A-K, Wiltfang J, Al-Nawas B, Naujokat H. Non-Interventional Prospective Observational Study of Platelet Rich Fibrin as a Therapy Adjunctive in Patients with Medication-Related Osteonecrosis of the Jaw. Journal of Clinical Medicine. 2022; 11(3):682. https://doi.org/10.3390/jcm11030682
Chicago/Turabian StyleBlatt, Sebastian, Maximilian Krüger, Peer W. Kämmerer, Daniel G. E. Thiem, Philipp Matheis, Anne-Katrin Eisenbeiß, Jörg Wiltfang, Bilal Al-Nawas, and Hendrik Naujokat. 2022. "Non-Interventional Prospective Observational Study of Platelet Rich Fibrin as a Therapy Adjunctive in Patients with Medication-Related Osteonecrosis of the Jaw" Journal of Clinical Medicine 11, no. 3: 682. https://doi.org/10.3390/jcm11030682